Reappraisal of Gestational Weight Gain Recommendations in Obese Pregnant Women: A Population-Based Study of 337,590 Births.


Journal

Obesity facts
ISSN: 1662-4033
Titre abrégé: Obes Facts
Pays: Switzerland
ID NLM: 101469429

Informations de publication

Date de publication:
2020
Historique:
received: 23 12 2019
accepted: 18 05 2020
pubmed: 31 8 2020
medline: 16 4 2021
entrez: 31 8 2020
Statut: ppublish

Résumé

Maternal obesity is an epidemic health problem that is aggravated by excessive gestational weight gain (GWG) and postpartum weight retention. Current US Institute of Medicine (now US National Academy of Medicine) guidelines (2009) for GWG need to be evaluated against the current rise in obesity in the general and pregnant population. We wanted to study the relation between GWG and pregnancy and birth outcomes and to relate this to the current recommendations for GWG. Population-based study. We performed an epidemiological analysis in a cohort of Belgian pregnant women with singleton live births at term (≥37 weeks) between 2009 and 2014 (n = 337,590). Logistic regression was used to determine the optimal GWG in relation to relevant pregnancy and birth outcomes. The prevalence of maternal obesity significantly increased from 10.3% in 2009 to 11.4% in 2014. The mean (SD) body mass index at the start of the pregnancy significantly increased from 23.9 (4.5) in 2009 to 24.2 (4.6) in 2014. Excessive GWG was frequent, especially in overweight (56.8%) and obese (52.9%) pregnant women. In the logistic regression model, the amount of GWG associated with the lowest incidence of both large-for-gestational-age and small-for-gestational-age infants was 21 kg in underweight women, 14 kg in normal weight, 8 kg in overweight, 0 kg in obese class I, -4 kg in obese class II and -5 kg in obese class III. The prevalence of maternal obesity has risen in Belgium between 2009 and 2014. Current GWG guidelines, based on historic observational data, are probably too liberal for class II and III obese women in which better outcomes are being predicted for lower weight gain than recommended.

Sections du résumé

BACKGROUND AND OBJECTIVE
Maternal obesity is an epidemic health problem that is aggravated by excessive gestational weight gain (GWG) and postpartum weight retention. Current US Institute of Medicine (now US National Academy of Medicine) guidelines (2009) for GWG need to be evaluated against the current rise in obesity in the general and pregnant population. We wanted to study the relation between GWG and pregnancy and birth outcomes and to relate this to the current recommendations for GWG.
METHODS
Population-based study. We performed an epidemiological analysis in a cohort of Belgian pregnant women with singleton live births at term (≥37 weeks) between 2009 and 2014 (n = 337,590). Logistic regression was used to determine the optimal GWG in relation to relevant pregnancy and birth outcomes.
RESULTS
The prevalence of maternal obesity significantly increased from 10.3% in 2009 to 11.4% in 2014. The mean (SD) body mass index at the start of the pregnancy significantly increased from 23.9 (4.5) in 2009 to 24.2 (4.6) in 2014. Excessive GWG was frequent, especially in overweight (56.8%) and obese (52.9%) pregnant women. In the logistic regression model, the amount of GWG associated with the lowest incidence of both large-for-gestational-age and small-for-gestational-age infants was 21 kg in underweight women, 14 kg in normal weight, 8 kg in overweight, 0 kg in obese class I, -4 kg in obese class II and -5 kg in obese class III.
CONCLUSION
The prevalence of maternal obesity has risen in Belgium between 2009 and 2014. Current GWG guidelines, based on historic observational data, are probably too liberal for class II and III obese women in which better outcomes are being predicted for lower weight gain than recommended.

Identifiants

pubmed: 32862185
pii: 000508975
doi: 10.1159/000508975
pmc: PMC7590778
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

333-348

Informations de copyright

© 2020 The Author(s) Published by S. Karger AG, Basel.

Références

Lancet. 2006 Sep 30;368(9542):1164-70
pubmed: 17011943
Am J Obstet Gynecol. 2013 Sep;209(3):214.e1-11
pubmed: 23635421
BJOG. 2014 Jan;121(1):72-81; discussion 82
pubmed: 24102880
BMJ. 2012 May 16;344:e2088
pubmed: 22596383
Am J Clin Nutr. 2014 Feb;99(2):312-9
pubmed: 24335054
Lancet Diabetes Endocrinol. 2015 Oct;3(10):767-77
pubmed: 26165396
Obstet Gynecol. 2013 Nov;122(5):999-1009
pubmed: 24104777
Eur J Obstet Gynecol Reprod Biol. 2016 Oct;205:98-104
pubmed: 27567535
Lancet Diabetes Endocrinol. 2017 Jan;5(1):53-64
pubmed: 27743978
Health Technol Assess. 2017 Aug;21(41):1-158
pubmed: 28795682
Diabetes Care. 2015 Sep;38(9):1650-6
pubmed: 26112044
JAMA. 2019 May 7;321(17):1702-1715
pubmed: 31063572
Syst Rev. 2017 Mar 9;6(1):51
pubmed: 28274270
BMJ. 2017 Feb 8;356:j1
pubmed: 28179267
JAMA. 2014 Feb 26;311(8):806-14
pubmed: 24570244
Am J Clin Nutr. 2008 Jun;87(6):1750-9
pubmed: 18541565
Lancet Diabetes Endocrinol. 2017 Jan;5(1):65-76
pubmed: 27743974
BMC Pregnancy Childbirth. 2019 Nov 21;19(1):434
pubmed: 31752763
Obstet Gynecol. 2015 Mar;125(3):566-75
pubmed: 25730217
JAMA. 2016 Jun 7;315(21):2284-91
pubmed: 27272580
BJOG. 2007 Feb;114(2):187-94
pubmed: 17305899
Obes Rev. 2008 Mar;9(2):140-50
pubmed: 18221480
Obes Rev. 2016 Nov;17(11):1091-1102
pubmed: 27536879
Obstet Gynecol. 2007 Oct;110(4):752-8
pubmed: 17906005
Diabetologia. 2019 Jun;62(6):915-925
pubmed: 30840112
Diabetologia. 2019 Feb;62(2):249-258
pubmed: 30421138
BJOG. 2016 Jan;123(2):207-16
pubmed: 26525168
Obesity (Silver Spring). 2013 Sep;21(9):1942-9
pubmed: 23408496
JAMA. 2017 Jun 6;317(21):2207-2225
pubmed: 28586887
Int J Obes (Lond). 2013 Jun;37(6):814-21
pubmed: 23032404
Eur J Obstet Gynecol Reprod Biol. 2016 Jun;201:203-8
pubmed: 27160501
PLoS Med. 2019 Jun 11;16(6):e1002817
pubmed: 31185012
Int J Gynaecol Obstet. 2007 Feb;96(2):138
pubmed: 17240378
Lancet Diabetes Endocrinol. 2016 Dec;4(12):1037-1049
pubmed: 27743977
Clin Obes. 2012 Oct;2(5-6):150-9
pubmed: 25586250
Am Heart J. 2019 Nov;217:84-93
pubmed: 31520898
BJOG. 2016 Jan;123(2):163-4
pubmed: 26841209
Can J Cardiol. 2018 May;34(5):526-531
pubmed: 29731014
JAMA. 2016 Jun 7;315(21):2292-9
pubmed: 27272581
Lancet Diabetes Endocrinol. 2016 Dec;4(12):1025-1036
pubmed: 27743975
Sex Reprod Healthc. 2017 Mar;11:47-52
pubmed: 28159128

Auteurs

Roland Devlieger (R)

Department of Development and Regeneration, KU Leuven, Leuven, Belgium, roland.devlieger@uzleuven.be.
Department of Obstetrics and Gynecology, University Hospitals Leuven, Leuven, Belgium, roland.devlieger@uzleuven.be.
Department of Obstetrics, Gynecology and Fertility, Gasthuiszusters Antwerpen, Campus St. Augustinus, Antwerp, Belgium, roland.devlieger@uzleuven.be.

Lieveke Ameye (L)

Department of Development and Regeneration, KU Leuven, Leuven, Belgium.
Data Centre - Biostatistical Unit, Jules Bordet Institute, Université Libre de Bruxelles, Brussels, Belgium.

Tinne Nuyts (T)

Department of Development and Regeneration, KU Leuven, Leuven, Belgium.

Régine Goemaes (R)

Study Centre for Perinatal Epidemiology (SPE), Brussels, Belgium.

Annick Bogaerts (A)

Department of Development and Regeneration, KU Leuven, Leuven, Belgium.
Faculty of Medicine and Health Sciences, Centre for Research and Innovation in Care (CRIC), University of Antwerp, Antwerp, Belgium.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH